Z Squared Inc. quarterly report, Q2 FY2025

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (trading symbol: COEP). Note: The request metadata referenced "Z Squared Inc.," but the filing text identifies the registrant as Coeptis Therapeutics Holdings, Inc., which entered into a pending merger agreement with Z Squared, Inc. on April 25, 2025.

Reporting Period: Quarterly period ended June 30, 2025 (Form 10-Q).

Business Overview: The Company operates as a holding company with two primary segments: Biotechnology (developing cell therapy platforms for cancer and autoimmune diseases) and Technology (AI-powered marketing software and robotic process automation via the NexGenAI platform). The Company is classified as a Non-accelerated Filer, Smaller Reporting Company, and Emerging Growth Company.

Key Financial Metrics

Metric Three Months Ended June 30, 2025 Six Months Ended June 30, 2025 As of June 30, 2025
Total Revenue $200,681 $263,555 -
Gross Profit $155,524 $173,242 -
Net Loss (Total) $(4,334,586) $(7,755,527) -
Net Loss (Attributable to Common Stockholders) $(3,534,595) $(6,592,325) -
Loss Per Share (Basic & Diluted) $(1.17) $(2.29) -
Cash and Cash Equivalents - - $1,996,726
Marketable Securities - - $990,566
Total Assets - - $12,191,479
Total Liabilities - - $5,111,349
Stockholders' Equity - - $7,080,130
Convertible Notes Payable (Net) - - $1,042,007
Notes Payable (Current, in Default) - - $100,000

Material Changes vs. Prior Period

  • Revenue Generation: The Company recorded $263,555 in revenue for the six months ended June 30, 2025, compared to $0 for the same period in 2024. This revenue is derived from the Technology segment (NexGenAI platform services).
  • Operating Expenses: Total operating expenses increased to $8,751,440 for the six months ended June 30, 2025, from $5,750,485 in the prior year period. The increase was driven primarily by professional services expenses ($5.3M vs. $2.0M) related to the pending Merger Agreement with Z Squared, Inc.
  • Net Loss: Net loss increased to $7.76M for the six months ended June 30, 2025, from $6.04M in the prior year period.
  • Liquidity: Cash and cash equivalents increased from $532,885 at December 31, 2024, to $1,996,726 at June 30, 2025, largely due to financing activities including a Series A preferred stock offering and proceeds from notes payable.
  • Derivative Liabilities: The Company recognized a gain of $798,430 for the six months ended June 30, 2025, due to changes in the fair value of derivative liabilities (warrants and SEPA), compared to a loss of $114,375 in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

  • Going Concern: The filing states that the Company's accumulated deficit of $105.99M and net losses raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt sales.
  • Pending Merger: On April 25, 2025, the Company entered into a Merger Agreement to acquire Z Squared, Inc. The transaction involves a spin-out of Coeptis's biotechnology operations prior to the merger. The merger is expected to close in 2025.
  • Debt Status: A $100,000 note payable is listed as "in default" as of June 30, 2025. Additionally, the Company has a Standby Equity Purchase Agreement (SEPA) with Yorkville, which includes a convertible note component.
  • Subsequent Events:
    • July 11, 2025: Commenced a private placement common stock offering ($2.5M - $5.0M).
    • July 14, 2025: Yorkville converted $1.14M of principal and interest into 158,582 shares of common stock.
    • July 29, 2025: Final 625 shares of Series A preferred stock were converted to common stock.
  • Internal Controls: Management concluded that disclosure controls and procedures were effective as of June 30, 2025, following remediation of material weaknesses identified in 2023.

Investor Verification Checklist

  • Merger Completion: Verify the status of the pending merger with Z Squared, Inc. and the execution of the biotechnology spin-out.
  • Debt Default: Confirm the status of the $100,000 note payable currently in default and any potential acceleration of other debt obligations.
  • Liquidity Runway: Assess the sufficiency of the $2.0M cash balance against the $7.8M net loss run rate and upcoming capital requirements for R&D and operations.
  • Revenue Sustainability: Evaluate the durability of the Technology segment revenue ($263k for six months) and the concentration risk (three customers accounted for 100% of advertising revenue).
  • Equity Dilution: Monitor the impact of the SEPA, convertible notes, and recent private placement on share count and per-share value.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.